TMCnet News
Affimed Establishes Scientific Advisory Board
HEIDELBERG, Germany, June 30, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today the establishment of a Scientific Advisory Board (SAB) of renowned experts in their respective fields to provide scientific and clinical guidance on the development of Affimed’s innate cell engagers (ICE®) programs. This newly formed advisory board includes the following scientific and clinical experts:
Dr. Fehniger of Washington University School of Medicine added, “This is an exciting time for innate immunity therapy development. Affimed has a robust pipeline and promising clinical data validating the research approach. I look forward to working with the company and the other members of the SAB in expediting timelines to make these promising therapies available to cancer patients.” The SAB members are leaders in a broad range of areas relevant to Affimed's approach to developing cancer therapies including immuno-oncology, the biology of NK cells, lymphomas, leukemias, and solid tumors. To learn more about the members of the new Scientific Advisory Board, please visit the “About Us” section of Affimed’s website at www.affimed.com. About Affimed N.V. Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to give patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company’s proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK® platform predictably generates customized innate cell engager (ICE®) molecules, which use patients’ immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE®. Headquartered in Heidelberg, Germany, with offices in New York, NY, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients’ lives. For more about the Company, its people, pipeline and partners, please visit www.affimed.com. Investor Relations Contact Alexander Fudukidis Media Contact Mary Beth Sandin |